Attune raises $23M, reports safety data for angioedema candidate

Rare diseases company Attune Pharmaceuticals (New York, N.Y.) raised $23 million on Jan. 23 in a series B round on the back of reporting Phase I data for its lead oral plasma kallikrein (KLKB1) inhibitor, ATN-249, to treat hereditary angioedema (HAE).

In a poster presentation Jan. 21, Attune reported that single ascending doses of oral ATN-249 led to no treatment-related moderate or severe adverse events and no dose-limiting toxicities among 48 healthy volunteers in the Phase I trial. Data were presented at the Western Society of Allergy, Asthma and Immunology meeting in Maui...